The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Molecular Determinants for the Tissue Specificity of SERMs
Abstract
Selective estrogen receptor modulators (SERMs) mimic estrogen action in certain tissues while opposing it in others. The therapeutic effectiveness of SERMs such as tamoxifen and raloxifene in breast cancer depends on their antiestrogenic activity. In the uterus, however, tamoxifen is estrogenic. Here, we show that both tamoxifen and raloxifene induce the recruitment of corepressors to target gene promoters in mammary cells. In endometrial cells, tamoxifen, but not raloxifene, acts like estrogen by stimulating the recruitment of coactivators to a subset of genes. The estrogen-like activity of tamoxifen in the uterus requires a high level of steroid receptor coactivator 1 (SRC-1) expression. Thus cell type– and promoter-specific differences in coregulator recruitment determine the cellular response to SERMs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription
Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., & Brown, M. (2000) · Cell · doi:10.1016/s0092-8674(00)00188-4 · Cited by 1,657
Self-citationRole of the Insulin-Like Growth Factor Family in Cancer Development and Progression
Yu, H. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.18.1472 · Cited by 1,424
Berry, M., Metzger, D., & Chambon, P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07469.x · Cited by 767
Tzukerman, M. T. (1994) · Molecular Endocrinology · doi:10.1210/me.8.1.21 · Cited by 671
Smith, C. S., Nawaz, Z., & O’Malley, B. W. (1997) · Molecular Endocrinology · doi:10.1210/me.11.6.657 · Cited by 662
Cited by
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Estrogen receptors: how do they signal and what are their targets
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. (2007) · Physiological Reviews · doi:10.1152/physrev.00026.2006 · Cited by 1,857
Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E., & Vergote, I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67063-8 · Cited by 1,497
Lehrke, M., & Lazar, M. A. (2005) · Cell · doi:10.1016/j.cell.2005.11.026 · Cited by 1,443
Carroll, J. S., Liu, X. S., Brodsky, A. S., Li, W., Meyer, C. A., Szary, A. J., Eeckhoute, J., Shao, W., Hestermann, E. V., Geistlinger, T. R., et al. (2005) · Cell · doi:10.1016/j.cell.2005.05.008 · Cited by 1,384
Self-citationGenome-wide analysis of estrogen receptor binding sites
Carroll, J. S., Meyer, C. A., Song, J., Li, W., Geistlinger, T. R., Eeckhoute, J., Brodsky, A. S., Keeton, E. K., Fertuck, K. C., Hall, G. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1901 · Cited by 1,377
Self-citationEstrogen receptors and human disease
Deroo, B. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27987 · Cited by 1,320
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Principles for modulation of the nuclear receptor superfamily
Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1551 · Cited by 1,226
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Skeletal remodeling in health and disease
Zaidi, M. (2007) · Nature Medicine · doi:10.1038/nm1593 · Cited by 1,069
Estrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in Osteoclasts
Nakamura, T., Imai, Y., Matsumoto, T., Sato, S., Takeuchi, K., Igarashi, K., Harada, Y., Azuma, Y., Krust, A., Yamamoto, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.025 · Cited by 1,013
Estrogen receptor signaling mechanisms
(2019) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/bs.apcsb.2019.01.001 · Cited by 988
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
Riggs, B. L., & Hartmann, L. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022219 · Cited by 968
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
Welshons, W. V., Thayer, K. A., Judy, B. M., Taylor, J. A., Curran, E. M., & vom Saal, F. S. (2003) · Environmental Health Perspectives · doi:10.1289/ehp.5494 · Cited by 905
De Bosscher, K., Vanden Berghe, W., & Haegeman, G. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0006 · Cited by 898
“, NCoR, SMRT, SRC-1, CBP) by means of RNAi (235, 460).”
Frasor, J., Danes, J. M., Komm, B., Chang, K. C. N., Lyttle, C. R., & Katzenellenbogen, B. S. (2003) · Endocrinology · doi:10.1210/en.2003-0567 · Cited by 876
Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, J., Allred, D. C., Clark, G. M., & Schiff, R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 786
LSD1 Is a Subunit of the NuRD Complex and Targets the Metastasis Programs in Breast Cancer
Wang, Y., Zhang, H., Chen, Y., Sun, Y., Yang, F., Yu, W., Liang, J., Sun, L., Yang, X., Shi, L., et al. (2009) · Cell · doi:10.1016/j.cell.2009.05.050 · Cited by 692
Self-citationOverview of nomenclature of nuclear receptors
Germain, P., Staels, B., Dacquet, C., Spedding, M., & Laudet, V. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.2 · Cited by 688
The role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2017) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 587
International Union of Pharmacology. LXIV. Estrogen Receptors
Dahlman-Wright, K., Cavailles, V., Fuqua, S. A., Jordan, V. C., Katzenellenbogen, J. A., Korach, K. S., Maggi, A., Muramatsu, M., Parker, M. G., & Gustafsson, J.-Å. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.8 · Cited by 583
Paruthiyil, S., Parmar, H., Kerekatte, V., Cunha, G. R., Firestone, G. L., & Leitman, D. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2446 · Cited by 576
Shanle, E. K., & Xu, W. (2011) · Chemical Research in Toxicology · doi:10.1021/tx100231n · Cited by 522
Protective actions of sex steroid hormones in Alzheimer’s disease
Pike, C. J., Carroll, J. C., Rosario, E. R., & Barron, A. M. (2009) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2009.04.015 · Cited by 522
Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy
Cui, X., Schiff, R., Arpino, G., Osborne, C. K., & Lee, A. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.004 · Cited by 514
Controlling nuclear receptors: the circular logic of cofactor cycles
Perissi, V., & Rosenfeld, M. G. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1680 · Cited by 510
Patel, H. K., & Bihani, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 499
Structure–function relationship of estrogen receptor α and β: Impact on human health
Ascenzi, P., Bocedi, A., & Marino, M. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.07.001 · Cited by 499
Estrogen Signaling and Cardiovascular Disease
Murphy, E. (2011) · Circulation Research · doi:10.1161/circresaha.110.236687 · Cited by 497
Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family
Xu, J., Wu, R.-C., & O'Malley, B. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2695 · Cited by 488
HDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel-Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 486
p21 and p27: roles in carcinogenesis and drug resistance
Abukhdeir, A. M., & Park, B. H. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000744 · Cited by 463
Wang, Q., Carroll, J. S., & Brown, M. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.07.018 · Cited by 450
Self-citationPeroxisome proliferator-activated receptor γ in diabetes and metabolism
Rangwala, S. M., & Lazar, M. A. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.03.012 · Cited by 450
Genomic Targets of Nuclear Estrogen Receptors
O’Lone, R., Frith, M. C., Karlsson, E. K., & Hansen, U. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0044 · Cited by 441
Stanczyk, F. Z., Hapgood, J. P., Winer, S., & Mishell, D. R. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1008 · Cited by 429
Arnal, J.-F., Lenfant, F., Metivier, R., Flouriot, G., Henrion, D., Adlanmerini, M., Fontaine, C., Gourdy, P., Chambon, P., Katzenellenbogen, B., et al. (2017) · Physiological Reviews · doi:10.1152/physrev.00024.2016 · Cited by 418
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020449y · Cited by 414
Selective Estrogen Receptor Modulators
Frasor, J., Stossi, F., Danes, J. M., Komm, B., Lyttle, C. R., & Katzenellenbogen, B. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3326 · Cited by 395
The unfolding stories of GPR30, a new membrane-bound estrogen receptor
Maggiolini, M., & Picard, D. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0242 · Cited by 360
Reflections on the Discovery and Significance of Estrogen Receptor β
Koehler, K. F., Helguero, L. A., Haldosén, L.-A., Warner, M., & Gustafsson, J.-A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0027 · Cited by 360
The Molecular Mechanism Governing the Oncogenic Potential of SOX2 in Breast Cancer
Chen, Y., Shi, L., Zhang, L., Li, R., Liang, J., Yu, W., Sun, L., Yang, X., Wang, Y., Zhang, Y., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802917200 · Cited by 358
Self-citationsiRNA-based approaches in cancer therapy
Devi, G. R. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700931 · Cited by 353
Estrogen-Receptor Biology: Continuing Progress and Therapeutic Implications
Osborne, C. K., & Schiff, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.036 · Cited by 351
Shi, B., Liang, J., Yang, X., Wang, Y., Zhao, Y., Wu, H., Sun, L., Zhang, Y., Chen, Y., Li, R., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00162-07 · Cited by 340
Self-citationGoetz, M. P., Sangkuhl, K., Guchelaar, H., Schwab, M., Province, M., Whirl‐Carrillo, M., Symmans, W. F., McLeod, H. L., Ratain, M. J., Zembutsu, H., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1007 · Cited by 336
Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer
Jordan, V. C., & O'Malley, B. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3886 · Cited by 324
The Role of Corepressors in Transcriptional Regulation by Nuclear Hormone Receptors
Privalsky, M. L. (2004) · Annual Review of Physiology · doi:10.1146/annurev.physiol.66.032802.155556 · Cited by 324
Selective estrogen receptor modulation
Jordan, V. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00059-5 · Cited by 315
Liang, J., & Shang, Y. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183708 · Cited by 314
Self-citationWu, W., Chaudhuri, S., Brickley, D. R., Pang, D., Karrison, T., & Conzen, S. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2546 · Cited by 314
The biological role of estrogen receptors α and β in cancer
Pearce, S. T., & Jordan, V. C. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.09.003 · Cited by 311
Integrative eQTL-Based Analyses Reveal the Biology of Breast Cancer Risk Loci
Li, Q., Seo, J.-H., Stranger, B., McKenna, A., Pe’er, I., LaFramboise, T., Brown, M., Tyekucheva, S., & Freedman, M. L. (2013) · Cell · doi:10.1016/j.cell.2012.12.034 · Cited by 308
Self-citationNuclear Receptor Coregulators and Human Disease
Lonard, D. M., Lanz, R. B., & O’Malley, B. W. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0012 · Cited by 302
Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved Selectivity
Komm, B. S., Kharode, Y. P., Bodine, P. V. N., Harris, H. A., Miller, C. P., & Lyttle, C. R. (2005) · Endocrinology · doi:10.1210/en.2005-0030 · Cited by 298
Hormone Therapy: Physiological Complexity Belies Therapeutic Simplicity
Turgeon, J. L., McDonnell, D. P., Martin, K. A., & Wise, P. M. (2004) · Science · doi:10.1126/science.1096725 · Cited by 297
Corepressors selectively control the transcriptional activity of PPARγ in adipocytes
Guan, H.-P., Ishizuka, T., Chui, P. C., Lehrke, M., & Lazar, M. A. (2005) · Genes & Development · doi:10.1101/gad.1263305 · Cited by 293
Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions
Rodriguez, A. C., Blanchard, Z., Maurer, K. A., & Gertz, J. (2019) · Hormones and Cancer · doi:10.1007/s12672-019-0358-9 · Cited by 291
Nuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance
Lewis, J. S., & Jordan, V. C. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2005.02.028 · Cited by 281
Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis
Wu, H., Chen, Y., Liang, J., Shi, B., Wu, G., Zhang, Y., Wang, D., Li, R., Yi, X., Zhang, H., et al. (2005) · Nature · doi:10.1038/nature04225 · Cited by 273
Self-citationLIGAND CONTROL OF COREGULATOR RECRUITMENT TO NUCLEAR RECEPTORS
Nettles, K. W., & Greene, G. L. (2005) · Annual Review of Physiology · doi:10.1146/annurev.physiol.66.032802.154710 · Cited by 268
Turgeon, J. L., Carr, M. C., Maki, P. M., Mendelsohn, M. E., & Wise, P. M. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0020 · Cited by 264
Transgenic Model of Aldosterone-Driven Cardiac Hypertrophy and Heart Failure
Qin, W., Rudolph, A. E., Bond, B. R., Rocha, R., Blomme, E. A. G., Goellner, J. J., Funder, J. W., & McMahon, E. G. (2003) · Circulation Research · doi:10.1161/01.res.0000080521.15238.e5 · Cited by 262
Michalides, R., Griekspoor, A., Balkenende, A., Verwoerd, D., Janssen, L., Jalink, K., Floore, A., Velds, A., van `t Veer, L., & Neefjes, J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.016 · Cited by 260
Pomegranate Fruit as a Rich Source of Biologically Active Compounds
Sreekumar, S., Sithul, H., Muraleedharan, P., Azeez, J. M., & Sreeharshan, S. (2014) · BioMed Research International · doi:10.1155/2014/686921 · Cited by 258
“The best move towards the avoidance and handling of estrogen-dependent breast cancer is to selectively hold estrogen activity in the affected tissues without compromising its beneficial effects [87].”
BackgroundMolecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis
Shang, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1879 · Cited by 246
Self-citationTiwari-Woodruff, S., Morales, L. B. J., Lee, R., & Voskuhl, R. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703783104 · Cited by 234
The c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
Frick, K. M. (2009) · Hormones and Behavior · doi:10.1016/j.yhbeh.2008.08.015 · Cited by 205
“Tamoxifen, a SERM used for the prevention and treatment of breast cancer in postmenopausal women, acts as an ER antagonist in tissues such as breast and an ER agonist in several tissues including bone, liver, and uterus (Mitlak and Cohen, 1997; Shang and Brown, 2002).”
BackgroundSelective estrogen receptor modulators: an update on recent clinical findings
Shelly, W., Draper, M. W., Krishnan, V., Wong, M., & Jaffe, R. B. (2008) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e31816400d7 · Cited by 193
Kolkhof, P., Jaisser, F., Kim, S.-Y., Filippatos, G., Nowack, C., & Pitt, B. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_76 · Cited by 180
Expanding functional diversity of the coactivators
Lonard, D. M., & O'Malley, B. W. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.01.001 · Cited by 172
Estrogen Regulation of MicroRNA Expression
Klinge, C. (2009) · Current Genomics · doi:10.2174/138920209788185289 · Cited by 156
Gurvich, C., Hoy, K., Thomas, N., & Kulkarni, J. (2018) · Brain Sciences · doi:10.3390/brainsci8090163 · Cited by 150
The Glucocorticoid Receptor: Isoforms, Functions, and Contribution to Glucocorticoid Sensitivity
Lockett, J., Inder, W. J., & Clifton, V. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae008 · Cited by 135
Gorres, B. K., Bomhoff, G. L., Morris, J. K., & Geiger, P. C. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2010.199018 · Cited by 116
Frasor, J., Danes, J. M., Funk, C. C., & Katzenellenbogen, B. S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502782102 · Cited by 82
Fuller, P. J., Yang, J., & Young, M. J. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0060 · Cited by 74
Two unsuccessful clinical trials on endometriosis and a few lessons learned
Guo, S.-W., & Olive, D. L. (2007) · Gynecologic and Obstetric Investigation · doi:10.1159/000098413 · Cited by 49
Estrogen Deficiency, Postmenopausal Osteoporosis, and Age-Related Bone Loss
Khosla, S., & Pacifici, R. (2013) · Osteoporosis · doi:10.1016/b978-0-12-415853-5.00046-7 · Cited by 31
Augmentation of estrogen receptor-mediated transcription by steroid and xenobiotic receptor
Rokutanda, N., Iwasaki, T., Odawara, H., Nagaoka, R., Miyazaki, W., Takeshita, A., Koibuchi, Y., Horiguchi, J., Shimokawa, N., Iino, Y., et al. (2008) · Endocrine · doi:10.1007/s12020-008-9091-9 · Cited by 11
“Since pCIP/TRAM-1/SRC-3 is highly expressed in MCF-7 cells [42], we used p/CIP constructs in our mammalian two-hybrid studies.”
MethodResult
Metadata
- Authors
- Shang, Y., & Brown, M.
- Venue
- Science
- Published
- 2002-03-29
- Volume
- 295
- Issue
- 5564
- Pages
- 2465-2468
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2045389096
- Cited by
- 1,146
- References
- 28
- FWCI
- 53.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.